It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Identifying molecular alterations occurring during cancer progression is essential for a deeper understanding of the underlying biological processes. Here we have analyzed cancerous and healthy prostate biopsies using nanoLC-MS(MS) to detect proteins with altered expression and N-glycosylation. We have identified 75 proteins with significantly changing expression during disease progression. The biological processes involved were assigned based on protein–protein interaction networks. These include cellular component organization, metabolic and localization processes. Multiple glycoproteins were identified with aberrant glycosylation in prostate cancer, where differences in glycosite-specific sialylation, fucosylation, and galactosylation were the most substantial. Many of the glycoproteins with altered N-glycosylation were extracellular matrix constituents, and are heavily involved in the establishment of the tumor microenvironment.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Research Centre for Natural Sciences, Eötvös Loránd Research Network, MS Proteomics Research Group, Budapest, Hungary (GRID:grid.425578.9) (ISNI:0000 0004 0512 3755); Semmelweis University, Ph.D. School of Pharmaceutical Sciences, Budapest, Hungary (GRID:grid.11804.3c) (ISNI:0000 0001 0942 9821)
2 Research Centre for Natural Sciences, Eötvös Loránd Research Network, MS Proteomics Research Group, Budapest, Hungary (GRID:grid.425578.9) (ISNI:0000 0004 0512 3755); Budapest University of Technology and Economics, Faculty of Chemical Technology and Biotechnology, Budapest, Hungary (GRID:grid.6759.d) (ISNI:0000 0001 2180 0451)
3 Research Centre for Natural Sciences, Eötvös Loránd Research Network, MS Proteomics Research Group, Budapest, Hungary (GRID:grid.425578.9) (ISNI:0000 0004 0512 3755); Eötvös Loránd University, Hevesy György Ph.D. School of Chemistry, Budapest, Hungary (GRID:grid.5591.8) (ISNI:0000 0001 2294 6276)
4 Research Centre for Natural Sciences, Eötvös Loránd Research Network, MS Proteomics Research Group, Budapest, Hungary (GRID:grid.425578.9) (ISNI:0000 0004 0512 3755)
5 Semmelweis University, 1St Department of Pathology and Experimental Cancer Research, Budapest, Hungary (GRID:grid.11804.3c) (ISNI:0000 0001 0942 9821)